Peter A Argenta1, Jordan Mattson2, Colleen L Rivard2, Elizabeth Luther2, Alexandra Schefter2, Rachel I Vogel2. 1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, MN, United States of America. Electronic address: argenta@umn.edu. 2. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, MN, United States of America.
Abstract
OBJECTIVE: Recent reports in both cervical and endometrial cancer suggest that minimally invasive surgery (MIS) had an unanticipated negative impact on long-term clinical outcomes, including recurrence and death. Given increasing use of robotic surgery since the LAP2 trial, we sought to compare the intermediate and long-term outcomes between those who underwent robotic surgery or laparoscopy for Stage I endometrial cancer. METHODS: We performed a retrospective review of patients from a single, large, academic, urban practice who underwent either laparoscopic or robot-assisted MIS (RA-MIS) for the treatment of endometrial carcinoma between 2006 and 2016, ensuring at least 5 years of potential follow-up. To adjust for differences in confounding variables between groups, propensity score-based inverse probability of treatment weighting (IPTW) was performed. Overall and recurrence-free survival were compared using Cox proportional hazards regression models adjusting for confounding weights. RESULTS: 1027 patients were included; 461 received laparoscopy and 566 received RA-MIS. RA-MIS use increased steadily during the study window, which resulted in longer mean surveillance in laparoscopy group (median 8.7 years versus 6.3 years, p < 0.001). RA-MIS was associated poorer recurrence-free (HR: 1.41, 95% CI: 1.12, 1.77) and overall survival (HR: 1.39, 95% CI: 1.06, 1.83). Disease-specific survival was also poorer in the RA-MIS group (HR: 3.51, 95% CI: 2.19, 5.63). Among those who recurred, median time to first recurrence was shorter in the RA-MIS group than the laparoscopy group (16.3 vs. 28.7 months, p = 0.07). CONCLUSION: RA-MIS was associated with poorer long-term patient outcomes. Our data in this lower-risk population indicate relevant clinical endpoints may be occurring during intermediate and long-term follow-up windows. These findings support a prospective evaluation of the long-term outcomes of RA-MIS.
OBJECTIVE: Recent reports in both cervical and endometrial cancer suggest that minimally invasive surgery (MIS) had an unanticipated negative impact on long-term clinical outcomes, including recurrence and death. Given increasing use of robotic surgery since the LAP2 trial, we sought to compare the intermediate and long-term outcomes between those who underwent robotic surgery or laparoscopy for Stage I endometrial cancer. METHODS: We performed a retrospective review of patients from a single, large, academic, urban practice who underwent either laparoscopic or robot-assisted MIS (RA-MIS) for the treatment of endometrial carcinoma between 2006 and 2016, ensuring at least 5 years of potential follow-up. To adjust for differences in confounding variables between groups, propensity score-based inverse probability of treatment weighting (IPTW) was performed. Overall and recurrence-free survival were compared using Cox proportional hazards regression models adjusting for confounding weights. RESULTS: 1027 patients were included; 461 received laparoscopy and 566 received RA-MIS. RA-MIS use increased steadily during the study window, which resulted in longer mean surveillance in laparoscopy group (median 8.7 years versus 6.3 years, p < 0.001). RA-MIS was associated poorer recurrence-free (HR: 1.41, 95% CI: 1.12, 1.77) and overall survival (HR: 1.39, 95% CI: 1.06, 1.83). Disease-specific survival was also poorer in the RA-MIS group (HR: 3.51, 95% CI: 2.19, 5.63). Among those who recurred, median time to first recurrence was shorter in the RA-MIS group than the laparoscopy group (16.3 vs. 28.7 months, p = 0.07). CONCLUSION: RA-MIS was associated with poorer long-term patient outcomes. Our data in this lower-risk population indicate relevant clinical endpoints may be occurring during intermediate and long-term follow-up windows. These findings support a prospective evaluation of the long-term outcomes of RA-MIS.
Authors: Jiheon Song; Tien Le; Laura Hopkins; Michael Fung-Kee-Fung; Krystine Lupe; Marc Gaudet; Choan E; Rajiv Samant Journal: Int J Gynecol Cancer Date: 2019-12-22 Impact factor: 3.437
Authors: Joel Cardenas-Goicoechea; Amanda Shepherd; Mazdak Momeni; John Mandeli; Linus Chuang; Herbert Gretz; David Fishman; Jamal Rahaman; Thomas Randall Journal: Am J Obstet Gynecol Date: 2013-10-28 Impact factor: 8.661
Authors: Jvan Casarin; Chao Song; Francesco Multinu; Serena Cappuccio; Emelline Liu; Kristina A Butler; Gretchen E Glaser; William A Cliby; Carrie L Langstraat; Fabio Ghezzi; Alex Z Fu; Andrea Mariani Journal: Gynecol Oncol Date: 2019-11-25 Impact factor: 5.482
Authors: Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma Journal: J Clin Oncol Date: 2012-01-30 Impact factor: 44.544
Authors: Monika Janda; Val Gebski; Lucy C Davies; Peta Forder; Alison Brand; Russell Hogg; Thomas W Jobling; Russell Land; Tom Manolitsas; Marcelo Nascimento; Deborah Neesham; James L Nicklin; Martin K Oehler; Geoff Otton; Lewis Perrin; Stuart Salfinger; Ian Hammond; Yee Leung; Peter Sykes; Hextan Ngan; Andrea Garrett; Michael Laney; Tong Yow Ng; Karfai Tam; Karen Chan; C David Wrede; Selvan Pather; Bryony Simcock; Rhonda Farrell; Gregory Robertson; Graeme Walker; Nigel R Armfield; Nick Graves; Anthony J McCartney; Andreas Obermair Journal: JAMA Date: 2017-03-28 Impact factor: 56.272
Authors: Alice B Kornblith; Helen Q Huang; Joan L Walker; Nick M Spirtos; Jacob Rotmensch; David Cella Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544